Utah hospital breaks ground on three-year expansion project

Alta View Hospital in Sandy, Utah, broke ground April 13 on what will be the largest investment project in the operation’s history, with major clinical improvements schedule for the next three years.

The additions include two four-story patient/clinic towers. Alta View Hospital, partnering with Intermountain Healthcare’s Transformation Lab, is incorporating new automated technologies to improve patient care. Some of those technologies include digital whiteboards with touch screen monitors and real-time location systems that help track assets and vehicles.

The actual groundbreaking featured a robot designed by four local high school students, who were challenged to build a replacement for hospital administrators. The use of robots represents Alta View’s emphasis on using technology to improve patient experience.

"With this construction project, we’re laying the foundation to better serve the families in our community,” said Bryan Johnson, an administrator at Alta View. "By updating inpatient rooms, maternity rooms, state-of-the-art surgical suites, and more, we’re preparing for the next three generations of families who will become part of the Alta View and Intermountain Healthcare families."

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.